IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.413
AS - Asia 7.957
EU - Europa 5.776
SA - Sud America 1.045
Continente sconosciuto - Info sul continente non disponibili 504
AF - Africa 364
OC - Oceania 15
AN - Antartide 1
Totale 27.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.088
CN - Cina 3.306
SG - Singapore 1.943
IE - Irlanda 1.480
HK - Hong Kong 984
BR - Brasile 767
VN - Vietnam 737
RU - Federazione Russa 701
FI - Finlandia 617
DE - Germania 615
IT - Italia 507
UA - Ucraina 477
FR - Francia 402
GB - Regno Unito 283
SE - Svezia 259
ZA - Sudafrica 240
IN - India 209
BD - Bangladesh 184
CA - Canada 152
AR - Argentina 89
MX - Messico 81
JP - Giappone 73
ES - Italia 71
IQ - Iraq 66
PL - Polonia 65
TR - Turchia 64
PK - Pakistan 51
NL - Olanda 50
CO - Colombia 46
AT - Austria 45
ID - Indonesia 43
VE - Venezuela 39
EC - Ecuador 38
BE - Belgio 37
PH - Filippine 35
SA - Arabia Saudita 34
MA - Marocco 31
LT - Lituania 24
JM - Giamaica 22
CL - Cile 21
CZ - Repubblica Ceca 21
AE - Emirati Arabi Uniti 20
IR - Iran 18
MY - Malesia 18
TN - Tunisia 17
UZ - Uzbekistan 17
AL - Albania 15
AU - Australia 15
EG - Egitto 15
GR - Grecia 15
KZ - Kazakistan 15
TH - Thailandia 15
JO - Giordania 13
KE - Kenya 12
LB - Libano 12
PY - Paraguay 12
UY - Uruguay 12
AZ - Azerbaigian 11
IL - Israele 11
RO - Romania 11
BG - Bulgaria 10
HN - Honduras 10
PT - Portogallo 10
CR - Costa Rica 9
ET - Etiopia 9
MU - Mauritius 9
PE - Perù 9
BO - Bolivia 8
CH - Svizzera 8
DK - Danimarca 8
KG - Kirghizistan 8
KR - Corea 8
PS - Palestinian Territory 8
DZ - Algeria 7
NI - Nicaragua 7
SV - El Salvador 7
LV - Lettonia 6
NP - Nepal 6
SK - Slovacchia (Repubblica Slovacca) 6
EU - Europa 5
GT - Guatemala 5
KH - Cambogia 5
NG - Nigeria 5
PA - Panama 5
SY - Repubblica araba siriana 5
BB - Barbados 4
BH - Bahrain 4
BN - Brunei Darussalam 4
BS - Bahamas 4
CU - Cuba 4
IS - Islanda 4
RS - Serbia 4
AM - Armenia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
KW - Kuwait 3
MK - Macedonia 3
Totale 26.506
Salva come PNG Salva come JPEG
Città #
Dublin 1.479
Chandler 1.325
San Jose 1.269
Singapore 1.003
Ashburn 1.000
Hong Kong 956
Dallas 847
Jacksonville 663
Beijing 660
Nanjing 570
Boardman 483
Council Bluffs 457
Lauterbourg 288
Los Angeles 267
Ho Chi Minh City 264
Helsinki 263
Princeton 259
Lawrence 251
Nanchang 250
Medford 242
Wilmington 210
Johannesburg 207
Hanoi 189
Shenyang 181
New York 177
Changsha 162
Hebei 162
Ann Arbor 143
Jiaxing 132
Munich 132
Buffalo 131
Santa Clara 130
Redondo Beach 121
Tianjin 118
Shanghai 109
Moscow 104
Hangzhou 97
Pavia 93
Milan 89
São Paulo 81
Piscataway 69
Orem 65
Tokyo 65
Woodbridge 64
Montreal 53
Norwalk 52
Warsaw 52
Frankfurt am Main 49
Seattle 46
Columbus 45
Denver 45
London 45
Turku 45
Atlanta 44
Chennai 43
Da Nang 40
Toronto 39
Chicago 38
Falkenstein 38
The Dalles 38
Houston 37
Nuremberg 37
Brussels 34
Phoenix 34
Brooklyn 33
Guangzhou 33
Pune 32
Stockholm 32
Fairfield 30
San Francisco 30
Haiphong 29
Poplar 27
Baghdad 25
Manchester 25
Mexico City 25
Amsterdam 24
Charlotte 24
Rio de Janeiro 24
Verona 24
Zhengzhou 24
Boston 23
Brasília 23
Ningbo 23
Des Moines 21
Vienna 21
Ankara 19
Rome 19
Washington 19
Curitiba 17
Dhaka 17
Medellín 17
Kunming 16
Caracas 15
Belo Horizonte 14
Guayaquil 14
Lahore 14
Querétaro 14
Tashkent 14
Hyderabad 13
Jinan 13
Totale 17.468
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 217
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 164
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 154
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 154
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 154
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 145
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 143
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 143
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 141
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 141
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 141
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 139
Amyloid typing: immunoelectron microscopy 137
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 136
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 135
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 134
AMICA: an electronic patient record specifically designed for an amyloidosis network 134
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 132
A patient with AL amyloidosis with negative free light chain results 130
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 129
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 129
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 129
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 128
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 128
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 127
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 127
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 126
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 126
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 126
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 126
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 125
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 125
Clotting alterations in primary systemic amyloidosis. 124
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 124
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 124
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 124
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 124
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 123
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 123
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 122
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 122
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 121
Hereditary amyloidosis 121
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 121
Bone marrow amyloidosis. 120
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 120
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 120
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 119
A practical approach to the diagnosis of systemic amyloidoses 118
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 117
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 117
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 116
Prognostication of survival and progression to dialysis in AA amyloidosis 116
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 116
Holter monitoring in AL amyloidosis: prognostic implications. 115
Biochemical markers in early diagnosis and management of systemic amyloidoses 115
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 115
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 114
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 113
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 113
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 113
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 112
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 112
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 111
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 111
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 111
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 111
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 110
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 110
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 110
A workflow management system for the biological samples exchange within the amyloidosis network 110
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 110
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 110
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 110
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 108
AMICA: an electronic patient record specifically designed for an amyloidosis network. 108
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 108
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 108
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 107
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 107
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 107
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 105
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 105
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 105
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options 105
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 104
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 104
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 104
Clinical aspects of systemic amyloid diseases. 103
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 103
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 103
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 103
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 102
Light chain amyloidosis 2012: a new era. 102
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 102
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 101
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 101
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 101
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 101
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. 100
Totale 12.020
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.338
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.338
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.071 0 0 26 11 32 19 11 91 61 42 155 623
2022/20233.826 436 278 47 286 351 350 24 211 1.690 20 85 48
2023/20241.412 181 304 48 109 126 295 33 86 12 43 100 75
2024/20254.073 85 295 96 111 70 283 201 254 990 181 479 1.028
2025/202610.875 774 723 1.049 1.208 1.432 419 1.949 518 1.032 786 480 505
2026/20271.020 363 596 61 0 0 0 0 0 0 0 0 0
Totale 27.075